Dr Glass discusses P2 smoking cessation trial results

ASX / MEDIA ANNOUNCEMENT Invion Limited ABN 76 094 730 417 GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com EVP R&D DR MITCHELL GLASS DISCUSS WITH BRR MEDIA DATA FROM THE PHASE II CLINICAL TRIAL OF INV102 (NADOLOL) IN SMOKING CESSATION Brisbane, Australia and Delaware, United States, 6 October 2015: Australian respiratory technology company Invion Limited (ASX: IVX) is delighted to invite investors to listen to Invion’s Dr Mitchell Glass discuss the results of the Phase II clinical trial of INV10 2 (nadolol) in patients trying to quit smoking, following the successful conclusion of the study. In this audiocast, Dr Glass discusses the following:  Phase 2 trial data demonstrates INV102 treated smokers were more likely to stop smoking completely or dramatically reduce the number of cigarettes smoked;  Data demonstrates that INV102 is a safe and effective treatment for patients with chronic bronchitis who are enrolled in smoking cessation programs;  Invion is preparing an FDA submission during Q4 2015 for End of Phase 2 Meeting request ; and  New data paves the way for INV102 to be developed as a novel inhaled treatment for chronic airway diseases including asthma, COPD and cystic fibrosis. To access the audiocast, please visit this link: http://www.brrmedia.com/event/140433 ------------------------------------------ About Invion Limited Invion is a life sciences company focussed on the development of treatments for major op portunities in respiratory and autoimmune disease . The Group has three drug assets in development across four development programs . INV102 (nadolol) is a beta adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium treat chronic inflammatory airway diseases. A large phase II study in smoking cessation reported successful data in Q4 2015 and feasibility for an inhaled version of the drug is well -progressed with 3M Drug Delivery Systems. A phase II asthma study funded by the US NIH is ongoing. INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build -up of mucus in the lungs. An approved oral therapy, Invion is developing an inhaled version of the drug. INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX), with its clinical headquarters in Delaware, USA. FOR MORE INFORMATION CONTACT Managing Director and CEO: Dr Greg Collier. P: 07 3295 0500 [email protected]

The release as fetched from its publisher. inviongroup.com ↗